Tests LY3457263 in adults with type 2 diabetes not reaching blood sugar goal
Tests LY3457263 against placebo in adults with type 2 diabetes on semaglutide or tirzepatide.
Plain-language title generated from the registry record
Registry title: A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Key facts
- Where
- Bayamón and San Juan, Puerto RicoSee the 2 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06897475, who can take part
Where in Puerto Rico
- Centro de Endocrinologia Alcantara GonzalezBayamón, Puerto RicoTaking people
- Mgcendo LlcSan Juan, Puerto RicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT06897475EU 2024-520328-27-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.Read full original descriptionShow less
A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide Who Failed to Achieve HbA1c Goal
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Inclusion: Have type 2 diabetes; Have HbA1c ≥7.5% to ≤10.5% at screening; Have a body mass index (BMI) of ≥27 kilograms per square meter (kg/m2) at screening; Have had a stable body weight for the three months prior to screening; On stable treatment dose of one of the following incretins for at least three months prior to screening:; Injectable semaglutide (1 and 2 milligram (mg)); Injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg).
Exclusion: Have a prior or planned surgical treatment for obesity; Have any of the following cardiovascular conditions within three months prior to screening:; acute myocardial infarction; cerebrovascular accident (stroke); unstable angina, or; hospitalization due to congestive heart failure; Have taken any medications or alternative remedies for weight loss within three months prior to screening; Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar coma; Have used insulin to control blood glucose within the past year (short-term use allowed); Current use of prohibited oral antihyperglycemic medication (OAM) (including but not limited to, Dipeptidyl Peptidase IV Inhibitors (DPP-4i) and meglitinides) may be randomized if the prohibited OAM treatment was discontinued at least 3 months prior to screening; If participant has been on stable doses (for at least three months) of up to three permitted OAMs (limited to metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, alpha-glucosidase inhibitors, sulfonylurea, and/or thiazolidinediones (TZD), they are permitted to participate in the study.